Pfizer was ranked the world’s most admired pharmaceuticals by the fortune magazine in 1997. In 1999, Pifizer celebrated its 150^th anniversary. Forbes magazine declared is “The company of the year”. In 2000, Pifizer and Warner-Lambert agreed on a $90 billion merger to form the new Pifizer, which would make Pifizer the world’s fastest growing major Pharma company in the coming decades. Pifizer was named as “One of the 25 global Most admired all stars” by the Fortune magazine.

In 1924, the company’s employee strength was only 306, but now it has increased to 1,22,2000 staff worldwide. Pifizer is decided to discovering and developing innovative medicines and making them available to people around the world.

Pfizer Reports:

Our business is fundamentally about saving, improving and enhancing lives, and we believe that by being successful as a business we provide the greatest benefit to society.Our commitment to being an exemplary corporate citizen is reflected in our extensive efforts to improve access to healthcare, the core focus of our philanthropic initiatives. Through our support of health initiatives, and by the generosity and compassion of our employees, we strive to make the community in which we operate a better place to live and work. At Pfizer, ‘Community’ is a Core value Building relationships within the communities in which Pfizer operates is high on the agenda of Pfizer. We recognize that constructive interaction with society and positive relationships with host communities are important to our success and are beneficial to the company, its employees and the people around. Support to the need of the community is an integral part of Pfizer’s round the year community development programs.

Our Philanthropic Focus

• Providing Access to Medicines
• Support to patient Groups
• Providing Health Literacy
• Spreading Disease Awareness
• Building Communities
• Education, Training and Capacity Building
• The Process of drug discovery.

At an estimated budget of $7.9 billion in 2004 for research and development (R&D), Pfizer Inc. boasts of the industry’s largest Pharmaceutical R&D organization: Pfizer Global Research and Development.

Pfizer’s search for new treatments spans hundreds of research projects across 18 therapeutic areas. This is much more than any other company. Our scientists, clinicians, technicians, and other professionals employ state-of-the-art tools ranging from robotic high-through put screening (a method pioneered by Pfizer) to sophisticated genomic studies, and deliver a steady stream of innovative new products that enhance human and animal health.

A half century ago, despite daunting odds and great risk, Pfizer pioneered the mass production of penicillin, thus ushering in the modern pharmaceutical era. Now, more than 12,500 Pfizer scientists at our research facilities around the world continue the quest for new medicines with the same pioneering spirit.

Today, Pfizer is poised at the cutting edge of science and biotechnology, a position that is strengthened by partnerships and links with more than 250 associates in academia and from within the industry. These partnerships provide Pfizer with access to novel R&D tools and to key data on emerging trends.

Going beyond medicines-In India, Pfizer instituted the first every Diseases management program – Healthy Heart TM in Cardio Vascular Disease (hypertension, chronic stable angina and dyslipidemia), in partnership with Apollo Hospital, Hyderabad and more recently with Apollo Hospital, Chennai.

Partner with Physician Associations to develop recommendations/guidelines of managing specific diseases.

Provide medical information to physicians on drugs as well as therapeutic areas that we operate in a Pharmaco-Vigilance system wherein we track adverse events reported by physicians.

Questions:

1. Does Pfizer fulfill its role as a global player? Justify your answer.
2. Has its growth around the globe helped developing countries? Comment.